Summary of Significant Accounting Policies (Tables)
|
12 Months Ended |
Dec. 31, 2016 |
|---|
| Summary of Significant Accounting Policies |
|
| Schedule operating expenses for comparative periods as previously reported and as presented after the reclassifications |
The operating expenses for comparative periods as previously reported and as presented after the reclassifications are as follows (in thousands):
|
|
|
Six months ended
December 31, 2015
|
|
Year ended
June 30, 2015
|
|
Year ended
June 30, 2014
|
|
|
|
|
As previously
reported
|
|
After
reclassification
|
|
As previously
reported
|
|
After
reclassification
|
|
As previously
reported
|
|
After
reclassification
|
|
|
Research and development
|
|
$
|
24,244
|
|
$
|
25,472
|
|
$
|
23,278
|
|
$
|
24,137
|
|
$
|
9,746
|
|
$
|
9,575
|
|
|
General and administrative
|
|
11,145
|
|
9,917
|
|
11,234
|
|
10,375
|
|
2,600
|
|
2,771
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
$
|
35,389
|
|
$
|
35,389
|
|
$
|
34,512
|
|
$
|
34,512
|
|
$
|
12,346
|
|
$
|
12,346
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of the reconciliation of cash, cash equivalents, and restricted cash |
The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same such amounts shown in the statement of cash flows (in thousands).
|
|
|
December 31,
2016
|
|
December 31,
2015
|
|
June 30,
2015
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
158,779
|
|
$
|
194,263
|
|
$
|
229,046
|
|
|
Restricted cash
|
|
4,017
|
|
4,508
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows
|
|
$
|
162,796
|
|
$
|
198,771
|
|
$
|
229,046
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of estimated useful lives of property, plant and equipment |
|
Computer equipment
|
|
3 to 5 years
|
|
|
Laboratory equipment
|
|
5 years
|
|
|
Office equipment
|
|
5 years
|
|
|
Leasehold improvements
|
|
the expected duration of the lease
|
|
|
| Schedule of numerator and denominator in the basic and diluted loss per share computation |
The following table reconciles the numerator and denominator in the basic and diluted loss per share computation (in thousands):
|
|
|
Year ended
December 31,
2016
|
|
Six months
ended
December 31,
2015
|
|
Year ended
June 30,
2015
|
|
Year ended
June 30,
2014
|
|
|
Numerator for basic and diluted loss per share
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(71,579
|
)
|
$
|
(23,000
|
)
|
$
|
(22,058
|
)
|
$
|
(11,601
|
)
|
|
Deemed dividend on convertible preferred shares
|
|
—
|
|
—
|
|
(14,735
|
)
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to ordinary shareholders
|
|
$
|
(71,579
|
)
|
$
|
(23,000
|
)
|
$
|
(36,793
|
)
|
$
|
(11,601
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator for basic and diluted loss per share
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of shares used to calculate basic and diluted loss per share
|
|
424,713,997
|
|
424,711,900
|
|
214,704,593
|
|
148,335,529
|
|
|
| Schedule of potentially dilutive equity instruments excluded from the diluted loss per share calculation |
|
|
|
Year ended
December 31,
2016
|
|
Six months
ended
December 31,
2015
|
|
Year ended
June 30,
2015
|
|
Year ended
June 30,
2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of share options(1)
|
|
45,882,791
|
|
31,203,477
|
|
31,473,477
|
|
10,057,700
|
|
|
Weighted average number of Preferred Shares(2)
|
|
—
|
|
—
|
|
122,848,381
|
|
—
|
|
|
(1)
|
|
The Company granted a total of 15,543,040 options from January 1, 2017 through to March 8, 2017.
|
|
(2)
|
|
Adaptimmune Limited issued 1,758,418 Series A Preferred Shares in September 2014. In April 2015, as part of the Company reorganization, the Series A Preferred Shares of Adaptimmune Limited were exchanged for Series A Preferred Shares of Adaptimmune Therapeutics Limited on a one-for-100 basis. The Series A Preferred Shares were converted into ordinary shares at a rate of 1:1 immediately prior to the Company’s initial public offering on NASDAQ in May 2015.
|
|